0.1596

2.62% -0.0043

Pre-market: .16 0.0004 +0.25%

Tnf Pharmaceuticals Inc (TNFA)

Overview News Price History Discussions Forecast

Tnf Pharmaceuticals Inc stock is traded at $0.1596, with a volume of 1.61M. It is down -2.62% in the last 24 hours and down -17.60% over the past month. TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms, Isomyosamine and Supera-CBD. Isomyosamine is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B. The company has one reportable segment focused on Isomyosamine.

Previous Close:

$0.1639

Open:

$0.1645

24h Volume:

1.61M

Relative Volume:

0.81

Market Cap:

$2.26M

Revenue:

Net Income/Loss:

$-23.66M

P/E Ratio:

-0.0115

EPS:

-13.84

Net Cash Flow:

$-10.14M

1W Performance:

-3.62%

1M Performance:

-17.60%

6M Performance:

-86.92%

1Y Performance:

+0.00%

1-Day Range:

$0.1567

$0.1689

1-Week Range:

$0.1564

$0.1848

52-Week Range:

$0.1509

$2.16

Tnf Pharmaceuticals Inc Stock (TNFA) Company Profile

Name

Tnf Pharmaceuticals Inc

Sector

Healthcare (1168)

Industry

Biotechnology (661)

Phone

856-848-8698

Address

1185 AVENUE OF THE AMERICAS, NEW YORK

Employee

Twitter

Next Earnings Date

Latest SEC Filings

TNFA's Discussions on Twitter

Compare TNFA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TNFA Tnf Pharmaceuticals Inc	0.1596	2.35M	0	-23.66M	-10.14M	-13.84
ONC Beone Medicines Ltd Adr	257.00	26.69B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	443.82	114.81B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.282	41.83M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	85.54	6.60B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	483.07	65.36B	14.09B	4.50B	2.96B	39.28

Tnf Pharmaceuticals Inc Stock (TNFA) Latest News

Jun 02, 2025

Analyzing TNF Pharmaceuticals (NASDAQ:TNFA) & Aspira Women’s Health (NASDAQ:AWH) - Defense World

Jun 02, 2025

May 22, 2025

Wells Fargo & Company Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - Defense World

May 15, 2025

May 10, 2025

TNF Pharmaceuticals amends bylaws to change voting requirements By Investing.com - Investing.com Nigeria

May 10, 2025

May 09, 2025

TNF Pharmaceuticals amends bylaws to change voting requirements - Investing.com

May 09, 2025

TNF Pharmaceuticals Amends Bylaws to Alter Voting Rules - TipRanks

May 09, 2025

TNF Pharmaceuticals announces promising study results By Investing.com - Investing.com Nigeria

May 09, 2025

May 08, 2025

TNF Pharmaceuticals announces promising study results - Investing.com Australia

May 08, 2025

TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists - Business Wire

May 08, 2025

Apr 30, 2025

A new trading data show TNF Pharmaceuticals Inc (TNFA) is showing positive returns. - Sete News

Apr 30, 2025

Let’s Jump Into The Magnite Inc (NASDAQ: MGNI) Stock Forecast - Marketing Sentinel

Apr 30, 2025

Apr 28, 2025

TNF Pharmaceuticals Inc Inc. (TNFA) Price Performance: A Guide to Financial Ratios - investchronicle.com

Apr 28, 2025

Is TNF Pharmaceuticals Inc (TNFA) worth investing in despite its overvalued state? - uspostnews.com

Apr 28, 2025

Apr 26, 2025

Gaining Ground: TNF Pharmaceuticals Inc (TNFA) Closes Lower at 0.25, Down -9.00 - DWinneX

Apr 26, 2025

Comparing TNF Pharmaceuticals (NASDAQ:TNFA) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World

Apr 26, 2025

Apr 25, 2025

TNF Pharmaceuticals Inc (NASDAQ:TNFA) Is Looking Good Over The Long Term, Dropped Nearly -46.01% Over A Month. – Marketing Sentinel - Marketing Sentinel

Apr 25, 2025

Apr 24, 2025

Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ - GlobeNewswire

Apr 24, 2025

Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.

Apr 24, 2025

Apr 23, 2025